The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; Delcath Systems; Histosonics; Incyte; Ipsen; Rafael Pharmaceuticals; SERVIER; Taiho Oncology
Research Funding - Actuate Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Esanik (Inst); Exelixis (Inst); FibroGen (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); SERVIER (Inst); Syros Pharmaceuticals (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
Other Relationship - Rafael Pharmaceuticals (Inst)
 
Kent A. Griffith
No Relationships to Disclose
 
David Bing Zhen
Consulting or Advisory Role - Cornerstone Pharmaceuticals; Ipsen; Jazz Pharmaceuticals
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Cornerstone Pharmaceuticals (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Legend Biotech (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst); TME Pharma (Inst)
 
Dustin A. Deming
Consulting or Advisory Role - Bayer; Foundation Medicine; Illumina; Lilly; Pfizer; Regeneron; Seagen; STRATA Oncology
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genentech; Jazz Pharmaceuticals; Merck; Merus
Research Funding - Actuate Therapeutics; Bristol-Myers Squibb; Exelixis; Faeth Therapeutics; Fujifilm; Immunovaccine; Lisata; Loxo/Lilly; Merck; NGM Biopharmaceuticals; Novocure; Nucana; Rafael Pharmaceuticals; Seagen
 
David Hsieh
No Relationships to Disclose
 
Devalingam Mahalingam
Consulting or Advisory Role - Amgen; OncoOne; Qurient
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Amgen; Merck KGaA; Oncolytics
 
Oxana V. Crysler
Research Funding - ACCRU (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Angela Tatiana Alistar
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Merck
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck; seagen
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
David L Bajor
Employment - University Hospitals Case Medical Center
Stock and Other Ownership Interests - Mirati Therapeutics
Consulting or Advisory Role - Guidepoint Global
Speakers' Bureau - Natera
Research Funding - Abbvie; Apexigen (Inst); Bristol-Myers Squibb/Celgene (Inst); Calithera Biosciences (Inst); GlaxoSmithKline (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Tesaro (Inst)
 
Thomas Enzler
Research Funding - Abbvie; Agenus; Amgen; Arcus Biosciences; AstraZeneca; AstraZeneca; BioMed Valley Discoveries (Inst); CanBas; ECOG-ACRIN; Exelixis; Hoosier Cancer Research Network; NeoImmuneTech; Taiho Oncology; Tvardi Therapeutics
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; BioMed Valley Discoveries; Seagen